Evogene Ltd.

Foreign Filer Report • Nov 14, 2022

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2022

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot P.O.B 4173, Ness Ziona, 7414002, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1Lavie Bio Investor Presentation.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD. (Registrant)

Date: November 14, 2022

By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer

Exhibit 99.1

Forward looking statement

This presentation contains "forward-looking to future events, and Lavie Bio (the "Company") and its parent, Evogene Ltd. ("Evogene"), may from time to time make other statements, regardings for future financial or operating results and/or other maters regarding or affecting or affecting or affecting or affecting us are considered "forward-looking statements" as defines Litigation Reform Act of 1995 the "PSIRA") and other securities laws, as amended. Statements that are not statements of his may be deemed to be forward-looking statements may be identified by the use of such words as "believe", "enticipate", "should", "planned", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation we divers, product pipeline, future sales, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene's and our technology,

Such statements are based on current expections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are may affect the Company's actual results and coults to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, and trends in the future may differ materially from what is expressed or inplied by such forward-looking statements due to a variety of factors, many of which are beyond our cirnitation, those described in greater detail in Evgene's Annual Report on Form 20-F and in other internes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws we obligation or commitment to update any information on this presentation or to publicy release the results of any revisions to any be made to reflect future events or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or offer to sell, or any solicitation of any invitation or offer to purche for, any securities of Eugene or the Company, nor shall the information or any part of the fact of its distribution form the basis of, or be relied on intract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

The Ag-Biologicals opportunity Driving healthier crops, sustainability and productive agriculture

The Ag-Biologicals untapped potential

	Crop Protection & Fertilizers	Ag-Biologicals Today
Sustainability	+	++++
Efficacy	++++	++
Consistency	++++	+
Commercial viability	++++	+

ნ

lavie bio

Improve food quality, sustainability and agriculture productivity through microbiome based ag-biologicals technology and products

The Power of the Microbiome

Billions of microbes make a difference!

The challenge: Discovering the right microbes and tailoring them for commercial use

8

Biology Driven Design platform

The microbiome OS

I Lavie Bio holds an exclusive license to use Even in the discovery and development of products in Lave Bio Sfield of activity.

2 As part of Corteva's investment in Lavie Bio in 2019, Lavie acquired the assets of Taxon Biosciences, including a large microbial collection.

Decoding the natural diversity of genetic functionality

Function-based product discovery & tailoring

Lavie Bio Next generation Ag-Biologicals

	Crop Protection & Fertilizers	Ag-Biologicals Today	Ag-Biologicals Next generation
Sustainability	+	++++	1
Efficacy	++++	++	1
Consistency	++++	+	1
Commercial viability	++++	+	+++ TT

Lavie Bio product pipeline

Thrivus™▶ INOCULANT

Bio-stimulants driving yield advantage

Sales in North America initiated in 2022

2022	2023- 2024*
USA - ND	USA - ND, MT
	Canada - Sasc. Man. AB.

*Expected geographic expansion.

Better than Bio-stimulants benchmarks tested

LAV311 & LAV312

Bio-fungicides against Botrytis & fruit rots

Expected launch in North America in 2024

Untreated

Better than ag-biologicals and potentially comparable to chemical benchmarks tested

Established 'End to End' capabilities

Business Model

Lavie Bio Product

• · End-to-end product development
• · Commercialization through direct channels
• . Revenues from sales

Lavie Bio 'tech-inside' product

• · Joint product development
• · Commercialization through partner's channels
• · Revenues from R&D /
  milestone payments and royalties,

Strategic Partners & Stakeholders

Ilavie bio

About Corteva Agriscience (NYSE: CTVA)

A global pure-play agriculture company that provides farmers with a complete portfolio - including a balanced and diverse mix of seed, crop protection and digital solutions focused on maximizing productivity to enhance yield and profitability.

Strategic Collaboration

In August 2019, Lavie Bio and Corteva Agriscience entered a multi-year collaboration, mainly focusing on the development of novel ag-biological products for corn and soybean.

Investment

Corteva's investment in Lavie Bio included a \$10 million equity investment along with the exchange of all shares of Corteva's wholly owned subsidiary Taxon Bioscience.

For more info read the press release https://evess.corteva-agriscience-to-invest-in-evogenes-agriculture-bologicals-subsidiany-lavie-bio/

Strategic Partners & Stakeholders

About ICL Group (NYSE: ICL)

A leading global specialty minerals company, which also benefits from commodity upside. The company creates impactful solutions for humanity's sustainability challenges in the global food, agriculture and industrial markets.

Strategic Collaboration

In August 2022, ICL and Lavie Bio entered a multi-year strategic collaboration for the development of novel bio-stimulant products.

Investment

ICL invested \$10 million in Lavie Bio.

For more info read the press release https://evogener-strategic-and-lavie-bio-enter-strategic-collaboration-to-develop-novel-bio-stimulant-products/

->

Management Team

Guri Oron

Michael lonesco

I VP Research

Innovative research leader with deep biotechnology, big data and informatics expertise

Board of Directors

Ofer Haviv

Chairman of the

Dor Kestecher

| VP Business Development

10+ years of broad experience leading in agriculture product management, strategy, and development

Amir Bercovitz

| VP Development

Extensive development and product expertise in the agbiologicals field for 30+ years - led introductions of 5 commercial products

Russel Putland

30+ years of ag commercial leadership roles with 'ground up' experience in large multi-national organizations

..

board Evogene CEO evogene

Elad Aharonson President of Innovative Ag Solutions for ICL AICL

Trevor Thiessen

CORTEVA

Frederic C. Beudot

Global Portfolio Leader for

Biologicals at Corteva Agriscience™

Senior agriculture executive, experienced in marketing, sales, and go-to-market MONSANTO novozymes:

Milestone Roadmap

• Bio-stimulant for wheat . initial product sales of 'Thrivus™' for spring wheat
• Fruit rot bio-fungicides . Product candidate advancement in regulation process for LAV311

• · Bio-stimulant for wheat 'Thrivus™' product sales expansion to MT, MN and Canada for spring wheat
• · Bio-stimulant for wheat 'Thrivus™' label expansion
• · Downy mildew bio-fungicides File for regulatory approval for leading product candidates LAV321 or LAV322
• · Additional product launch

Thank you!